We initially focused our attention on the BAFF pathway, because it is the only TNFRSF pathway that depends chiefly on non-canonical NF-κB signaling37 and should therefore be fully inhibited by NIK SMI1, and also because the BAFF blocking antibody Belimumab is an FDA-approved drug for lupus, thus representing an ideal benchmark. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.